Micafungina Hikma (Micafungin)

Micafungin blocks the enzyme β-(1,3)-D-glucan synthase, preventing the formation of β-(1,3)-D-glucan, an essential polymer of the fungal cell wall. Without this structural component, the cell wall becomes weak, leading to osmotic lysis and death of susceptible Candida species.

The dosing regimen for micafungin is individualized by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and treatment setting. Healthcare professionals determine the appropriate dose and infusion duration according to current clinical guidelines.

Micafungina Hikma is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It should be used in pregnancy only if the potential benefit justifies any potential risk. Limited data are available for breastfeeding, so a risk‑benefit assessment is required.

To request Micafungina Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to ergosterol. Echinocandins like micafungin are generally well‑tolerated, have fewer drug‑interaction concerns than azoles, and are fungicidal against most Candida species, making them a preferred option for invasive infections.

Micafungina Hikma should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use, and follow aseptic techniques when preparing the intravenous solution.

The medication is given as an intravenous infusion over a period typically ranging from 30 to 60 minutes, depending on the prescribed dose and clinical protocol. Administration should be performed by qualified healthcare personnel in a setting equipped for IV therapy and patient monitoring.

Serious adverse events, although uncommon, include severe hypersensitivity reactions (anaphylaxis), significant hepatic dysfunction, acute renal impairment, severe hypotension, Stevens‑Johnson syndrome, and eosinophilic pneumonia. Prompt recognition and discontinuation of therapy are essential if any of these events occur.

Micafungina Hikma is contraindicated in patients with a known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with pre‑existing severe liver or kidney disease, and it should be used only after careful risk assessment in pregnant or breastfeeding women.